Premium
Metabolic acidosis and anaemia associated with dorzolamide in a patient with impaired renal function
Author(s) -
Hoffmanová Iva,
Sánchez Daniel
Publication year - 2018
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.13499
Subject(s) - metabolic acidosis , dorzolamide , medicine , renal function , acidosis , kidney disease , carbonic anhydrase inhibitor , endocrinology , carbonic anhydrase , acetazolamide , impaired renal function , pharmacology , glaucoma , ophthalmology , chemistry , biochemistry , enzyme , timolol
Topical carbonic anhydrase inhibitors (CAI), used for treatment of glaucoma, are generally regarded as safe and unconnected with systemic side effects. We report an unusual case of fatigue, metabolic acidosis, and normocytic anaemia associated with ocular administration of the CAI, dorzolamide, in a patient with impaired renal function. In chronic kidney disease, where CAI elimination may be decreased, and patients prone to develop metabolic acidosis, systemic absorption of ocular administered CAI could lead to rare, but potentially serious adverse reaction, that are a consequence of inhibition of extraocular carbonic anhydrase isoenzymes.